Integral Single-cell Landscape of Immunological Hallmarks for Ankylosing Spondylitis

Not Applicable

Completed

• Conditions: Ankylosing Spondylitis

• Registration Number: NCT06846021
• Lead Sponsor: Fujian Provincial Hospital

Brief Summary

Three HLA-B27-positive health donors (HDs) with matching age were enrolled via genetic screening, and fourteen AS patients were recruited at Fujian provincial hospital from May to July 2021. All AS patients satisfied the modified New York (NY) criteria, and the categorization of three disease groups (EA, LD and RM) was according to clinical hallmarks and imaging evidences. The five patients in the EA group were in the early stage of disease, showing obvious symptoms, and had not yet received standard treatments, including various NSAIDs and DMARDs. The five patients in the LD group were all disabled, and confirmed by radiographic evidence of structural damage in hip joints and spinal deformity. The four patients in the RM group received standardized treatment under the guidance of specialist doctors, and maintained clinical remission and normal laboratory indicators for over six months. Patients in both EA and RM groups were confirmed to have no structural damage or deformities by radiographic evidences.

Detailed Description

Not available

Study Timeline

• Study Start: 2021-05-17
• Primary Completion: 2021-06-30
• Study Completion: 2021-08-25
• Status Verified: 2025-02
• Study First Submitted: 2025-02-12
• Study First Submitted QC: 2025-02-20
• Study First Posted: 2025-02-25
• Last Update Submitted: 2025-02-27
• Last Update Posted: 2025-03-04

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 17

Inclusion Criteria

Clinical diagnosis of ankylosing spondylitis Clinical hallmarks and imaging evidences

Exclusion Criteria

Pregnant patients Other diseases, tumors and injuries

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Assessment of the immunological characteristics regarding the onset and outcomes of ankylosing-spondylitis patients relying on single-cell transcriptomics analysis for four groups of subjects (including health donors and patients in early active stage, l	8 months

Trial Locations

Locations (1)

Orthopedic Outpatient Room; 🇨🇳 Fuzhou, China